CheckMate-067 · 2017 · New England Journal of Medicine
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs.
Source publication
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine · 2017
Sponsor
Bristol-Myers Squibb
Principal investigator
Bristol-Myers Squibb
Population
Unresectable or Metastatic Melanoma; n=945
Primary endpoint
Progression Free Survival (PFS)
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$1.6M / $2.7M
58%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1